Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15157057 | 0.85 | KMT2A (0.56) | LMNAALDH1A1KMT2ACXCR3AR | |
| SCHEMBL10203092 | 0.84 | FABP4 (0.41) | LMNAKMT2ACXCR3ARFABP4 | |
| SCHEMBL10203772 | 0.81 | AR (0.40) | ALDH1A1KMT2ACXCR3ARFABP4 | |
| SCHEMBL2012127 | 0.81 | NPY5R (0.44) | LMNAL3MBTL1KMT2AHTR1ARAD52 | |
| SCHEMBL10165383 | 0.80 | GRIN2B (0.41) | CXCR3ARSLC6A4 | |
| SCHEMBL10165551 | 0.80 | AR (0.43) | ALDH1A1KMT2ACXCR3ARSCN9A | |
| SCHEMBL14397085 | 0.79 | BACE1 (0.45) | LMNAKMT2ARAD52HTR2AHTR2C | |
| SCHEMBL15157143 | 0.78 | ALDH1A1 (0.47) | LMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL2831472 | 0.75 | HTR2A (0.56) | LMNAALDH1A1L3MBTL1KMT2AAR | |
| SCHEMBL12383523 | 0.74 | CYP19A1 (0.45) | ARHTR1ASLC6A4HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-02-22 | — | — | US | claimed |
| CN-1768036-A | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB SA (BE) | 2006-05-03 | — | — | CN | claimed |
| US-7964593-B2 | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2011-06-21 | — | — | US | disclosed |
| US-20100069375-A1 | Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2010-03-18 | — | — | US | disclosed |
| US-7645887-B2 | 2-(5-iodo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; epilepsy, epileptogenesis, seizure disorders and convulsion; 2-(5-chloro-2-oxo-2,3-dhydro-1H-indol-1-yl)-N-[6-(hydroxymethyl)cyclohex-3-en-1-yl]acetamide | UCB PHARMA, S.A. (BE) | 2010-01-12 | — | — | US | disclosed |
| CN-100364973-C | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB SA (BE) | 2008-01-30 | — | — | CN | disclosed |
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-02-22 | — | — | US | disclosed |
| CN-1768036-A | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB SA (BE) | 2006-05-03 | — | — | CN | disclosed |
| EP-1620399-A1 | INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004087658-A1 | INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069375-A1 | Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses | AANAT, TPH2, CYP1A2 | LMNA 1352/4885ALDH1A1 308/4885L3MBTL1 4870/4885 |
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | AANAT, TPH2, CYP1A2 | LMNA 1352/4885ALDH1A1 308/4885L3MBTL1 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.